GenMark Diagnostics Inc. (NASDAQ:GNMK) changes shares on Monday trading session, with a change of 16.31% or $1.69 shares. The trading starts at $10.32 and closed at $10.36 throughout the day. The trading session low price was $10.32 and day high was $12.10 on Monday, June 15. After the session, the Healthcare sector daily volume shifted to 2.54 million while its average volume is 3.12M. In other hand, the GNMK market cap reached to $791.69M. While, its current target price is $12.05 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 32.13% and up 0.58% for month. Its quarterly performance was 165.42% above, while its half year performance is up 124.81%. GNMK yearly performance stood at positive 78.25% and rise 150.52% for year-to-date. Current recommendation for GenMark Diagnostics Inc. is 1.90.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. GNMK EPS (TTM) for 12-month is -0.73. EPS for this year is 9.40%, while for the next year its value is -0.27. Its EPS Q/Q reached 45.90%. It has an EPS of 2.30% up for past five years.
Let’s take a look on the analyst recommendations on GNMK for the current month and previous month. For the current month, 5 of 7 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $12.00-$16.00. Average target price for GNMK was reached at $14.40.
FMR, LLC, Morgan Stanley and Blackrock Inc. are the top three holders in GenMark Diagnostics Inc. (GNMK) stock. On Mar 30, 2020, FMR, LLC has 9.12 million shares which valued 37.56 million. On Mar 30, 2020, Morgan Stanley owned 4.59 million shares which valued at 18.92 million. On Mar 30, 2020, Blackrock Inc. has a total of 4.27 million shares which valued at 17.61 million. In the end, Blackrock Inc. have 6.91% shares outstanding of GenMark Diagnostics Inc. (GNMK) on Mar 30, 2020. The insider ownership moved to 5.90% and institutional holding shifted to 75.40%.
The company posted an EPS (TTM) of -0.73. According to the most recent quarter report on (Jun 2020), 7 analysts estimated an average EPS of -0.11, while -0.23 EPS posted a year ago period. Analyst Estimated EPS for GNMK published in the report was -0.13–0.08 during the same period. Comparing with last year, the average estimated EPS was -0.23 which is lower than -0.12 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for GNMK rise 90.86% for period of 200 days. SMA for 50 days was 26.51% which is showing green signal, while SMA-20 was 22.68%. The moving average value for GenMark Diagnostics Inc. (GNMK) is 6.62 and 10.73 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in GNMK stock. On Jun 08, O’Brien Scott Alexander, SVP, Global Mktg & Int’l Sales, sold 780 trading shares at the cost of $9.14, which valued at 7129.0. On Jun 01, Mitchell Brian Andrew, SVP, Operations, sold 4,000 shares at the cost of $9.72, with total shares of 234,808. On May 28, Mitchell Brian Andrew, SVP, Operations, sold 2,021 shares at the cost of 9.52. After this transaction, Mitchell Brian Andrew total shares reached to 238,808 which valued at 19240.0.